


ACHIEVE MORE TOGETHER
CERTIFICATE OF ANALYSIS

Page 1/2

FINISHED PRODUCT			
Product name :	CLAVASEPTIN 500 10 CY HU RO	Analytical code :	426057
Pharmaceutical form :	Not Coated Tablets	Manufacturing date :	03/07/2018 /
Batch number :	8C2151D	Expiration date :	02/07/2021 /
TESTS	SPECIFICATIONS	RESULTS	
Characteristics of tablets	Oblong, off-white to brownish sprinkled, scored	Pass	
Length	$\geq 20.8 \leq 21.2$ mm	21.1 mm	
Average weight and uniformity of weight			
Average mass	$\geq 904.4 \leq 999.6$ mg	953.3 mg	
Uniformity of mass	Complies with EP 2.9.5.	Pass	
Resistance to crushing	≥ 80 N	138 N	
Disintegration test	≤ 15 min	< 4 min	
Equilibrium relative humidity	≤ 15 %	10 %	
Amoxicillin dissolution rate	Q=85% within 30 min	100 %	
Amoxicillin dissolution compliance	Complies with EP 2.9.3.	Pass	
Clavulanic ac dissolution rate	Q=80% within 30 min	105 %	
Clavulanic ac dissolution compliance	Complies with EP 2.9.3.	Pass	
Amoxicillin and clavulanic acid identity (HPLC)			
Amoxicillin UV spectrum	Positive	Pass	
Amoxicillin retention time	Positive	Pass	
Clavulanic acid UV spectrum	Positive	Pass	
Clavulanic acid retention time	Positive	Pass	
Amoxicillin and clavulanic acid assay			
Amoxicillin content	$\geq 380 \leq 420$ mg/tablet	404 mg/tab.	
Clavulanic acid content	$\geq 97.8 \leq 108.2$ mg/tablet	103.4 mg/tab.	

This document has been produced electronically and is valid without a signature.

LABORATOIRE PHARMACEUTIQUE VÉTÉINAIRE

Magny-Vernois | B.P.189 | 70204 Lure Cedex (France) | TÉL. : +33 (0) 3 84 62 55 55 - FAX : +33 (0) 3 84 62 55 56
VETODUINOL S.A. au Capital de 29.704.755 € | SIRET 676 250 111 00017 | RCS VESOUL GRAY B 676 250 111

PHOENIX Pharma 21-
Fóti Telephely
2151 Fót, Keleti Márton út 19.
..... sz. másolati példány
Csak a piros szín hiteles!
20-03



CERTIFICATE OF ANALYSIS

Page 2/2

FINISHED PRODUCT

Product name :	CLAVASEPTIN 500 10 CY HU RO	Analytical code :	426057
Pharmaceutical form :	Not Coated Tablets	Manufacturing date :	03/07/2018
Batch number :	8C2151D	Expiration date :	02/07/2021

TESTS	SPECIFICATIONS	RESULTS
Amoxicillin purity (HPLC)		
Imp.A	<= 1.0 %w/w	<0.3 % w/w
Imp.B	<= 1.0 %w/w	<0.3 % w/w
Imp.C	<= 1.0 %w/w	<0.3 % w/w
Imp.D	<= 1.0 %w/w	<0.3 % w/w
Imp.E	<= 1.0 %w/w	<0.3 % w/w
Imp.F	<= 1.0 %w/w	0.4 % w/w
Imp.G	<= 1.0 %w/w	0.3 % w/w
Imp.K	<= 1.0 %w/w	<0.3 % w/w
Any unidentified degradation product	<= 1.0 %w/w	<0.3 % w/w
Total unidentified degradation products	<= 2.0 %w/w	<0.3 % w/w
Total degradation products	<= 3.0 %w/w	0.7 % w/w
Clavulanic acid impurities (HPLC)		
Any unspecified degradation product	<= 1.0 %area	<0.3 % area
Total degradation products	<= 2.0 %area	<0.3 % area

I hereby certify that this lot is manufactured, packed and labelled under conditions as stated in the current European Union rules for Good Manufacturing Practice for medicinal products for veterinary use, and that the finished product in all aspects answers the requirements laid down in the marketing authorisation.

Released by Qualified Person :	Brian LOYON
Date :	22/10/2018 11:03:35
Decision :	FULL RELEASE

This document has been produced electronically and is valid without a signature.

LABORATOIRE PHARMACEUTIQUE VÉTÉRINAIRE

Magny-Vernois | B.P.189 | 70204 Lure Cedex (France) | TÉL. : +33 (0) 3 84 62 55 55 - FAX : +33 (0) 3 84 62 55 56
 VETOQUINOL S.A. au Capital de 29.704.755 € (SIRET 676 250 111 00017) | RCS VESOUL GRAY B 676 250 111

PHOENIX Pharma
 Fóti Telephely
 2151 Fót, Keleti Márton út 19.
 Minbiztonsági példány
 Csak a piros szín hiteles!
 20-02